Introduction
============

Urological cancers (UCs) constitute a significant percentage of newly diagnosed cancer cases and are being detected in increasing numbers in the aging population. Prostate cancer (PC), kidney cancer (KC), and bladder cancer (BC) constitute 4.5%, 2.1%, and 1.8%, respectively, of newly diagnosed cancer cases in Korea \[[@b1-crt-2018-053]\]. Additionally, the rapidly increasing elderly population in Korea, as well as the adoption of a westernized diet and a growing trend of performing routine health checkups has led to a recent increase in the incidence of PC, KC, and BC with an annual percentage change of 13.6%, 6.0%, and 1.5%, respectively \[[@b1-crt-2018-053]\].

Notably, survival of patients with UCs has also improved over time owing to early diagnosis and availability of advanced treatment \[[@b2-crt-2018-053]-[@b4-crt-2018-053]\]. The 5-year relative survival rates for PC, KC, and BC have risen to 99%, 74%, and 79%, respectively, in the United States \[[@b3-crt-2018-053]\], 84.8%, 56.3%, and 55.5%, respectively, in United Kingdom \[[@b4-crt-2018-053]\], and 93.3%, 81.3%, and 75.6%, respectively, in Korea \[[@b1-crt-2018-053],[@b2-crt-2018-053]\]. Thus, the number of UC survivors has increased, and their health-related qualityof-life (HRQoL) issues have been gaining attention, although this is to a lesser extent than that observed with other cancers such as breast, lung, and colorectal cancers. Moreover, previous quality of life (QoL) studies with respect to UCs have primarily focused on issues that are specific to a particular type of cancer (e.g., voiding and sexual function in PC and BC patients) or a comparison of HRQoL based on the treatment method used in each category of UC patients. Few studies have adequately addressed general HRQoL issues including functioning and symptoms, perceived social support, and depression among UC survivors. Moreover, few studies have analyzed the HRQoL of UC survivors compared to that of the general population.

Understanding the general QoL issues of UC survivors would help clinicians provide comprehensive care to them. In this study, we aimed to assess the general HRQoL among disease-free survivors of surgically treated PC, KC, and BC and to compare these results with the corresponding parameters obtained from the general population that served as controls.

Materials and Methods
=====================

1. Cancer survivors
-------------------

We identified UC survivors who had undergone curative surgery for PC, KC, and BC at four University Hospitals between 2011 and 2013. Inclusion criteria for the study were as follows: (1) patients aged ≥ 50 years, (2) those who were diagnosed with one of the three types of UCs after undergoing curative surgery, and (3) those without any evidence of recurrence for at least 1 year after surgery \[[@b5-crt-2018-053]\]. Although QoL may decline considerably after active cancer treatment and remain low for a short period thereafter, many side effects are acute and short-lived, and the majority of disease-free cancer survivors report good QoL 1-year post-treatment \[[@b5-crt-2018-053]\]. A total of 374 patients were selected during their regular visits to their urologists at outpatient clinics between April 2014 and December 2015. Exclusion criteria were (1) patients with other primary cancers (n=17), (2) patients with metastatic disease (n=1), and (3) patients aged \< 50 years or those with difficulties in communication due to mental or cognitive impairment (n=25). Thus, our study population comprised 331 UC survivors (114 PC, 108 KC, and 109 BC). None of UC survivors underwent adjuvant or salvage treatment after curative surgery.

To determine the general HRQoL in each UC survivors following various surgical methods that are used in clinical practice, we did not confine our study to any particular type of surgery, if it was performed with curative intent. For example, while all PC survivors had been treated with a radical prostatectomy (RP: 18 open, 92 robot-assisted, and 4 laparoscopic), KC survivors had been treated with a radical nephrectomy (65 patients \[60.2%\]: 29 open, 3 robot-assisted, and 33 laparoscopic) or a partial nephrectomy (43 patients \[39.8%\]: 18 open, 17 robot-assisted, and 8 laparoscopic). Among the BC survivors, 68 (62.4%), 23 (21.1%), 15 (13.8%), and three (2.7%) patients, respectively, underwent transurethral resection of bladder tumor, radical cystectomy with ileal conduit, neobladder reconstruction, and cutaneous diversion, respectively. UC survivors who consented to participate in our study were instructed to complete the survey questionnaire, and assistance was provided to them if they had difficulties in understanding the questionnaire items or had visual difficulties.

2. Control subjects
-------------------

The general population comprised respondents of the nation-wide survey, which was performed between November and December 2012. The survey has been described in detail by previous reports \[[@b6-crt-2018-053],[@b7-crt-2018-053]\]. The questionnaire included HRQoL, perceived social support, and depression, as well as sociodemographic and medical information pertaining to the participants. To ensure representativeness of the sample, a stratified probability sampling using a two-stage systematic sampling method was employed---after stratifying the population based on region, we systematically extracted samples based on the population ratio. The sampling error within a 95% confidence interval was ±2.2%. The participants were limited to those who were within an age range of 40-70 years (considering the purpose of the study) and those without a history of cancer. Trained interviewers from a professional research company visited the identified households to check/identify candidates eligible for participation.

Among 4,851 eligible individuals who were contacted, 2,000 individuals without cancer consented to participate in the study and completed the survey questionnaire (response rate, 41.2%). The primary reasons for non-participation were lack of time (54%), concern about privacy (25%), and inconvenience (17%).

For the comparison with the UC survivors (age range 50-96 years based on enrollment) and general population (age range 40-70 years based on inclusion criteria), we limited the age of the study population to 50-70 years. Thus, 1,176 individuals without cancer were included in the comparison. The number of UC survivors who were included in the comparison with control was 63 for PC, 84 for KC, and 69 for BC, respectively.

3. Instruments to measure quality of life
-----------------------------------------

We used three valid and reliable questionnaires---the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30), the Duke-UNC Functional Social Support Questionnaire (FSSQ) and the Patient Health Questionniare-9 (PHQ-9) to assess diverse aspects of general HRQoL among UC survivors.

### 1) Quality of Life

The EORTC QLQ-C30 is a 30-item questionnaire to assess the HRQoL of cancer patients \[[@b8-crt-2018-053],[@b9-crt-2018-053]\] and includes five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), global health status, and six single items (dyspnea, sleep disturbance, appetite loss, constipation and diarrhea, and financial difficulties). Participants responded to items using the 4-point Likert scale with responses varying from 1 (not at all) to 4 (very much), and two items of the global health/QoL scale were assessed using a 7-point Likert scale. The domain scores were calculated based on the EORTC QLQ-C30 scoring manual, and its Korean version was validated \[[@b9-crt-2018-053]\].

### 2) Perceived social support

The Duke-UNC FSSQ was used to measure each individual's perception of the degree and type of social support available/received \[[@b10-crt-2018-053]\]. The Korean version of the Duke-UNC FSSQ demonstrated high reliability and moderate validity \[[@b11-crt-2018-053]\]. Eight items from the Duke-UNC FSSQ comprising two sub-scales (Confidant and Affective support) were used to calculate the mean social support score \[[@b12-crt-2018-053]\]. The Confidant support sub-scale (comprising 5 items) assesses confidant support, i.e., support from those who are identified as a confidant with whom important life matters are discussed and shared. The Affective support sub-scale (comprising 3 items) assesses the general emotional support and care from family and friends. Responses to each question are scored on a 5-point scale, yielding a total score between 8 and 40. Higher scores suggest higher levels of perceived social support.

### 3) Depressive symptoms

The PHQ-9 is a 9-item self-report questionnaire designed to screen, diagnose, monitor, and assess the severity of depression \[[@b13-crt-2018-053]\]. The validity of the PHQ-9 is established among the Korean population \[[@b14-crt-2018-053]\]. For each item, patients rate the severity of their symptoms that are noted over 2 weeks prior to the assessment. The items pertain to a loss of interest, depressed mood, changes in sleep, energy, appetite, or eating habits, feelings of guilt or worthlessness, levels of concentration, feelings of being slowed down or restlessness, and suicidal ideation. Each item is rated on a 4-point Likert scale from 0 (not at all) to 3 (nearly every day).

4. Statistical analysis
-----------------------

The characteristics of UC survivors and the general population have been presented as numbers and means. We performed the analysis in a systematic manner: (1) initially, we analyzed the differences in HRQoL, perceived social support, and depression among the three groups of UC survivors using the analysis of covariance (ANCOVA) after adjusting for age, sex, Surveillance, Epidemiology, and End Results (SEER, <https://seer.cancer.gov/>) cancer summary stage, time interval since initiation of treatment, education level, employment status, smoking status, and alcohol consumption. (2) Next, survivors with each type of UC were compared with the general population that was studied as the control group using the ANCOVA for all the above-mentioned covariates except the SEER cancer summary stage, and time since initiation of treatment, which were not relevant to the control group. (3) Comparison with non-cancer controls was repeated after categorization of UC survivors into the short-term (1-2 years) and long-term (\> 2 years) categories for each type of cancer \[[@b15-crt-2018-053]\]. All statistical analyses were performed using the STATA ver. 14.0 software (Stata Corp., College Station, TX).

5. Ethics statement
-------------------

The study protocol was approved by the Institutional Review Board of the Eulji University Hospital (No. 2014-03-002) and the National Cancer Center (IRB No. NCCNCS-12-635). All participants were fully informed as to the purpose of the study and provided written consent.

Results
=======

1. Characteristics of UC survivors and general population non-cancer control
----------------------------------------------------------------------------

[Table 1](#t1-crt-2018-053){ref-type="table"} summarizes the sociodemographic and medical factors of UC survivors. Mean age was 66.5 years, 86.7% were men, 86.4% were married, and 58.6% reported high school level of educational qualifications or higher. Approximately 50% of the UC survivors reported a household income of ≥ 200 million Korean Won (1 USD=1,150 KRW as of year 2016), and approximately 50% reported being currently employed. We observed that 14.2% reported current smoking and 45.6% reported current alcohol consumption. Most tumors were localized (90.6%). Approximately 50% of UC survivors were at the 1- to 2-year time point after treatment, and only 16.6% were at a time point \> 5 years after cancer treatment. [Table 2](#t2-crt-2018-053){ref-type="table"} shows the sociodemographic factors pertaining to UC survivors and general population non-cancer controls, whose age was between 50 and 70 years. The general population group was significantly younger, showed higher educational and income levels and a higher tendency to engage in smoking and drinking behaviors.

2. Comparison of HRQoL, FSSQ, and depression among survivors of the three major types of UC
-------------------------------------------------------------------------------------------

No significant difference was observed between the PC, KC, and BC survivor groups with respect to all domains of the EORTC QLQ-C30 functioning and symptom scales, except for a slight but significant difference in social functioning between KC and BC survivors (89.5 vs. 80.6, respectively; p=0.021). The three groups did not significantly differ in terms of functional social support or depression ([Table 3](#t3-crt-2018-053){ref-type="table"}).

3. Comparison of HRQoL between PC, KC, and BC survivors and the general population
----------------------------------------------------------------------------------

When compared to the non-cancer general population, PC and BC survivors showed significantly lower social functioning and a lower appetite. KC survivors showed lower physical functioning, as well as higher pain and dyspnea symptoms. All three groups of UC survivors reported higher financial difficulties but also higher perceived social support than that reported by non-cancer controls ([Table 4](#t4-crt-2018-053){ref-type="table"}). There was no significant difference in depressive symptoms between each group of UC survivors and the general population ([Table 4](#t4-crt-2018-053){ref-type="table"}).

When examined by time elapsed from curative surgery, varying patterns were noted based on the type of cancer ([Fig. 1](#f1-crt-2018-053){ref-type="fig"}). PC survivors showed significantly diminished social functioning \> 2 years postsurgery, whereas other functioning scales and QoL did not significantly differ from the control group over time. Perceived social support was greater during the short-term survivorship period; however, it decreased thereafter. KC survivors showed decreased short-term physical, role, and social functioning, which did recover thereafter. QoL of KC survivors improved over time and it was significantly better than controls \> 2 years postsurgery, whereas perceived social support significantly increased after surgery and was sustained \> 2 years postsurgery. BC survivors showed significantly diminished social function, which did not recover \> 2 years postsurgery. Perceived social support of BC survivors significantly increased during the short-term survivorship period and was sustained thereafter. There were no statistically significant differences in terms of emotional and cognitive function, as well as depressive symptoms among the three UC survivor groups, regardless of the time elapsed from surgery ([Fig. 1](#f1-crt-2018-053){ref-type="fig"}).

Discussion
==========

To our knowledge, this is the first study to compare the general QoL issues among disease-free survivors of the three most common UCs and between each group of UC survivors and the general population in terms of HRQoL, perceived social support, and depression.

In our study, in broad terms, we did not observe significant differences in functioning sub-scales and symptoms, functional social support, and depression among the three groups of UC survivors, or when these groups were compared to the general population. This finding indicates that the general HRQoL observed in disease-free UC survivors is usually not compromised, as opposed to the changes observed with respect to disease-specific domains of HRQoL. This suggests that UC survivors can enjoy a QoL comparable to that of the general population and should be encouraged to resume their usual normal personal and social activities. An exception observed in this study was the significantly lower social functioning noted among BC survivors than that noted among KC survivors ([Table 3](#t3-crt-2018-053){ref-type="table"}). In our study, approximately one-third of BC survivors underwent a radical cystectomy with urinary diversion, and this may contribute, at least in part, to the limitations in social activities demonstrated in this group, as shown by previous studies \[[@b16-crt-2018-053]\].

Compared to non-cancer controls, PC survivors showed lower social functioning ([Table 4](#t4-crt-2018-053){ref-type="table"}), which seemed to worsen \> 2 years postsurgery ([Fig. 1](#f1-crt-2018-053){ref-type="fig"}). A German study has reported that social functioning among PC survivors who underwent RP was significantly lower than that observed in the general population, whereas other EORTC QLQ-C30 scales were similar to those observed in controls---a finding that is in agreement with that observed in our study \[[@b17-crt-2018-053]\]. Although urinary incontinence improves gradually over time after RP and recovers to baseline status approximately at 1-year postsurgery in most PC survivors, a few (approximately 10%) of survivors continue to report urinary symptoms and incontinence even \> 2 years post-RP \[[@b18-crt-2018-053]\]. The fear and embarrassing prospect of urine leakage, and the odor of urine associated with incontinence, as well as the need for diapers is humiliating to some PC survivors, which may interfere with their social life resulting in social withdrawal \[[@b19-crt-2018-053]\]. Additionally, sexual dysfunction can reduce sexual intimacy with partners and may affect family life, resulting in diminished social functioning \[[@b19-crt-2018-053]\]. Notably, sexual function declines in a majority of PC survivors after surgery and continues to show alterations in a significant percentage of them even \> 2 years post-RP \[[@b18-crt-2018-053],[@b20-crt-2018-053]\]. We consider that worsening social functioning \> 2 years postsurgery observed in PC survivors can be understood in such a disease-specific context.

KC survivors showed significantly lower physical functioning than that observed in the general population. To date, only two studies \[[@b21-crt-2018-053],[@b22-crt-2018-053]\] have compared HRQoL between KC survivors and non-cancer controls and have reported conflicting results: a study performed in the United States \[[@b21-crt-2018-053]\] using the 36-Item Short Form Health Survey (SF-36) and the RAND-12 questionnaire (vs. the EORTC QLQ-C30 used in our study) showed no significant differences in the HRQoL between the two study groups, and a Norwegian study \[[@b22-crt-2018-053]\] showed that KC survivors, particularly those undergoing surgery via an open or a flank approach, showed a lower HRQoL including a significantly higher pain score than that observed in the general population \[[@b22-crt-2018-053]\]. Our study also showed higher pain and dyspnea symptoms among KC survivors (among these, 43.5% \[47/108\] underwent open surgery). In terms of the time elapsed from the time of curative surgery until assessment ([Fig. 1](#f1-crt-2018-053){ref-type="fig"}), KC survivors showed diminished physical, role, and social functioning in the shortterm (1-2 years postsurgery); however, this finding was observed to resolve over time indicating that KC survivors have the capacity to positively adapt themselves to challenges that they face after cancer diagnosis and treatment. We reckon that this may be a possible explanation for the significantly higher QoL noted in KC survivors \> 2 years postsurgery than that observed in controls.

BC survivors showed significantly lower social functioning than that observed in the general population ([Table 4](#t4-crt-2018-053){ref-type="table"}), similar to the results noted in PC survivors. Interestingly, compromised social function observed among BC survivors was more evident 1-2 years postsurgery, which did not completely recover thereafter ([Fig. 1](#f1-crt-2018-053){ref-type="fig"}). BC survivors, particularly those who underwent a radical cystectomy (one-third of the BC population) reported urinary incontinence and sexual dysfunction, which might significantly contribute to lower social functioning. A Japanese study \[[@b16-crt-2018-053]\] reported that patients undergoing radical cystectomy, regardless of the procedure performed (neobladder reconstruction vs. ileal conduit) showed significantly lower social functioning than that observed in the general population of the United States, similar to the results of our study.

Of note, changes in social functioning noted postoperatively was a finding common to all three UC groups, although the pattern of change showed marginal differences between groups based on the type of cancer. Thus, clinicians should be mindful of changes in social functioning among UC survivors and consider appropriate supportive measures such as group education \[[@b23-crt-2018-053]\] and psychosocial intervention \[[@b24-crt-2018-053]\] to minimize compromised social functioning.

UC survivors reported significantly higher levels of perceived social support than that reported by the non-cancer control group, which is consistent with the literature \[[@b25-crt-2018-053]\]. Cancer survivors usually receive greater encouragement and supportive care from friends, colleagues, and family members than would be expected in the general population. However, perceived social support among PC survivors was observed to have worsened \> 2 years postsurgery, as opposed to that observed among KC or BC survivors. The reasons for this difference in pattern are unknown, although it could be related to lower sexual functioning noted even \> 2 years postsurgery among PC survivors.

We noted that the depression score measured by the PHQ-9 did not show any statistically significant difference in all the analyses performed, suggesting that the occurrence of depression is not significantly different in disease-free UC survivors, compared to non-cancer general population. However, a recent systematic review reported the prevalence of post-treatment depression in PC survivors to be as high as 18.4% \[[@b26-crt-2018-053]\], and the prevalence of major depressive disorder among PC or BC survivors was higher than that observed among survivors with breast or colorectal cancer in a nation-wide Korean study population \[[@b27-crt-2018-053]\], although these studies did not compare cancer survivors with controls from the general population. Given the paucity of research regarding depression among UC survivors, further studies are warranted to specifically determine an association, if any, between UC and its treatment and occurrence of depression in this population.

Limitations of our study are as follows: (1) because ours was a cross-sectional study, we were unable to assess HRQoL changes presurgery and postsurgery. Thus, our interpretation regarding HRQoL in terms of time elapsed from surgery may have been biased. (2) The relatively small sample size of our study is another limitation. Potential differences could not be detected due to low statistical power, and comparison of HRQoL according to the type of surgery was difficult due to the same reason. (3) Because our results came from only UC survivors who underwent curative surgery, our results cannot be generalized to overall PC, KC, and BC survivors. Despite these limitations, we reckon that our results analyzing general QoL, perceived social support, and depression reflect the overall HRQoL aspects associated with UC survivors and would help to provide greater insight into the critical QoL issues among UC survivors.

In conclusion, although general QoL issues were observed to be essentially similar among disease-free survivors of the 3 major types of UCs, a few differences were observed between these groups based on the type of cancer. BC in both short-and long-term and, to a lesser degree, PC survivors in the long-term demonstrated lower social functioning than non-cancer control, potentially associated with a non-sustained level of perceived social support. In contrast, KC survivors demonstrated lower physical functioning than non-cancer control in the short-term, perhaps associated with complaints of increased pain and dyspnea commonly noted during this period. No significant difference was observed in depressive symptoms between each group of UC survivors and the general population. Further studies with larger sample sizes and a longitudinal follow-up design would be required in this context. Our results will be useful to both urologists and patients because they provide information regarding the general QoL among UC survivors postsurgery and would help to plan for future supportive care needs.

Conflict of interest relevant to this article was not reported.
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###### 

Characteristics of urological cancer survivors (age ≥ 50)

                                  Prostate cancer (n=114)   Kidney cancer (n=108)   Bladder cancer (n=109)   All cancers (n=331)
  ------------------------------- ------------------------- ----------------------- ------------------------ ---------------------
  **Age (yr)**                    68.4±7.1                  63.1±9.1                68.0±9.2                 66.5±8.8
  **Sex**                                                                                                    
   Male                           114 (100)                 77 (71.3)               96 (88.1)                287 (86.7)
   Female                         0                         31 (28.7)               13 (11.9)                44 (13.3)
  **Marital status**                                                                                         
   Unmarried                      14 (12.3)                 13 (12.0)               17 (15.6)                44 (13.3)
   Married                        99 (86.8)                 95 (88.0)               92 (84.4)                286 (86.4)
  **Education**                                                                                              
   \< High school                 52 (45.6)                 36 (33.3)               45 (41.3)                133 (40.2)
   ≥ High school                  62 (54.4)                 69 (63.9)               63 (57.8)                194 (58.6)
  **Income (KRW)**                                                                                           
   \< 200 million                 60 (52.6)                 51 (47.2)               67 (61.5)                178 (53.8)
   ≥ 200 million                  54 (47.4)                 54 (50.0)               40 (36.7)                148 (44.7)
  **Job status**                                                                                             
   Unemployed                     52 (45.6)                 52 (48.2)               52 (47.7)                156 (47.1)
   Employed                       62 (54.4)                 53 (49.1)               56 (51.4)                171 (51.7)
  **Smoking**                                                                                                
   Non or past                    103 (90.4)                88 (81.5)               93 (85.3)                284 (85.8)
   Current                        11 (9.7)                  20 (18.5)               16 (14.7)                47 (14.2)
  **Drinking**                                                                                               
   Non or past                    62 (54.4)                 71 (66.5)               61 (57.6)                194 (59.3)
   Current                        52 (45.6)                 36 (33.6)               45 (45.4)                133 (40.6)
  **SEER stage**                                                                                             
   *In situ* or localized         95 (83.3)                 103 (95.4)              102 (93.6)               300 (90.6)
   Regional                       19 (16.7)                 5 (4.6)                 7 (6.4)                  31 (9.4)
  **Time since treatment (yr)**                                                                              
   1-2                            66 (57.9)                 39 (36.1)               48 (44.0)                153 (46.2)
   2-5                            39 (34.2)                 40 (37.0)               44 (40.4)                123 (37.2)
   \> 5                           9 (7.9)                   29 (26.9)               17 (15.6)                55 (16.6)

Values are presented as mean±standard deviation or number (%). Numbers may not sum to total number due to missing responses

###### 

Characteristics of urological cancer survivors and general population for comparison with non-cancer control (age 50-70)

                           General population (n=1,176)   All cancers (n=216)   p-value    Prostate cancer (n=63)   Kidney cancer (n=84)   Bladder cancer (n=69)
  ------------------------ ------------------------------ --------------------- ---------- ------------------------ ---------------------- -----------------------
  **Age (yr)**             57.8±5.4                       61.5±6                \< 0.001   63.4±5.1                 59.1±5.7               62.6±6.3
  **Sex**                                                                                                                                  
   Male                    568 (48.3)                     184 (85.2)            \< 0.001   63 (100)                 59 (70.2)              62 (89.9)
   Female                  608 (51.7)                     31 (14.4)                        0                        24 (28.6)              7 (10.1)
  **Marital status**                                                                                                                       
   Unmarried               67 (5.7)                       23 (10.6)             0.001      6 (9.5)                  8 (9.5)                9 (13.0)
   Married                 1,109 (94.3)                   191 (88.4)                       56 (88.9)                75 (89.3)              60 (87.0)
  **Education**                                                                                                                            
   Less than high school   314 (26.7)                     73 (33.8)             \< 0.001   29 (46.0)                26 (31.0)              18 (26.1)
   High school and above   862 (73.3)                     139 (64.4)                       34 (54.0)                54 (64.3)              51 (73.9)
  **Income (KRW)**                                                                                                                         
   \< 200 million          287 (24.4)                     93 (43.1)             \< 0.001   26 (41.3)                32 (38.1)              35 (50.7)
   ≥ 200 million           889 (75.6)                     118 (54.6)                       37 (58.7)                48 (57.1)              33 (47.8)
  **Job status**                                                                                                                           
   Unemployed              406 (34.5)                     85 (39.4)             0.001      24 (38.1)                34 (40.5)              27 (39.1)
   Employed                770 (65.5)                     128 (59.3)                       39 (61.9)                47 (56.0)              42 (60.9)
  **Smoking**                                                                                                                              
   Non or past             858 (73.0)                     179 (82.9)            0.001      58 (92.1)                65 (77.4)              56 (81.2)
   Current                 318 (27.0)                     36 (16.7)                        5 (7.9)                  18 (21.4)              13 (18.8)
  **Drinking**                                                                                                                             
   Non or past             398 (33.8)                     119 (55.1)            0.001      30 (47.6)                51 (60.7)              38 (55.1)
   Current                 778 (66.2)                     94 (43.5)                        33 (52.4)                31 (36.9)              30 (43.5)

Values are presented as mean±standard deviation or number (%). Numbers may not represent sum of total number due to missing responses. p-value (calculated by t test and chi-square test) represents comparison between general population and all urological cancer survivors.

###### 

Comparison of health-related quality of life, functional social support, and depression among survivors of three major types of urological cancer

                                  Prostate cancer (n=114)   Kidney cancer (n=108)   Bladder cancer (n=109)   p-value for difference                                
  ------------------------------- ------------------------- ----------------------- ------------------------ ------------------------ ------ ----- ------- ------- ------------------------------------------------------
  **EORTC QLQ C-30**                                                                                                                                               
   Functioning scales                                                                                                                                              
    Physical functioning          85.0                      1.6                     83.5                     1.8                      81.4   1.6   0.838   0.257   0.670
    Role functioning              86.4                      2.0                     88.7                     2.3                      82.9   2.0   0.763   0.439   0.148
    Emotional functioning         82.4                      1.9                     85.2                     2.0                      82.2   1.8   0.636   0.997   0.558
    Cognitive functioning         82.5                      1.7                     82.5                     1.9                      81.6   1.7   1.000   0.937   0.940
    Social functioning            86.8                      2.2                     89.5                     2.4                      80.6   2.1   0.712   0.111   0.021^[\*](#tfn1-crt-2018-053){ref-type="table-fn"}^
   Overall quality of life        57.7                      2.4                     64.0                     2.6                      62.9   2.3   0.234   0.272   0.949
   Symptom scales                                                                                                                                                  
    Fatigue                       26.4                      2.1                     23.4                     2.3                      25.5   2.0   0.636   0.950   0.774
    Nausea and vomiting           2.3                       0.9                     3.5                      1.0                      4.5    0.9   0.690   0.195   0.748
    Pain                          8.9                       2.0                     11.5                     2.2                      14.7   2.0   0.704   0.109   0.569
    Dyspnea                       13.5                      2.1                     16.4                     2.3                      13.9   2.1   0.683   0.988   0.735
    Sleep disturbance             21.6                      2.7                     15.8                     3.0                      21.1   2.6   0.370   0.990   0.394
    Appetite loss                 10.4                      1.9                     6.5                      2.1                      9.2    1.8   0.402   0.894   0.606
    Constipation                  18.4                      2.7                     14.6                     2.9                      21.0   2.6   0.660   0.756   0.256
    Diarrhea                      9.2                       2.0                     11.9                     2.2                      13.5   1.9   0.685   0.286   0.864
    Financial difficulties        17.4                      2.7                     19.4                     3.0                      20.6   2.7   0.890   0.685   0.959
  **Functional social support**                                                                                                                                    
   Affective support              7.1                       0.3                     6.9                      0.4                      7.6    0.3   0.870   0.586   0.321
   Confidant support              11.2                      0.5                     10.7                     0.6                      12.0   0.5   0.831   0.621   0.305
  **Depression**                  3.8                       0.4                     2.8                      0.4                      3.3    0.4   0.315   0.646   0.751

Adj. mean, adjusted mean by analysis of co-variance with age, sex, Surveillance, Epidemiology, and End Results cancer stage, time since treatment, education, employment status, smoking, alcohol consumption as covariates; SE, standard error; PC, prostate cancer; KC, kidney cancer; BC, bladder cancer; EORTC QLQ C-30, European Organization for Research and Treatment of Cancer.

p \< 0.05.

###### 

Comparison of health-related quality of life, functional social support, and depression between survivors of three major types of urological cancer and general population non-cancer control

                                  General population (n=1,176)   Prostate cancer (n=63)   Kidney cancer (n=84)   Bladder cancer (n=69)                                                                                                                                              
  ------------------------------- ------------------------------ ------------------------ ---------------------- ----------------------- ------------------------------------------------------ ------ ----- --------------------------------------------------------- ------ ----- ---------------------------------------------------------
  **EORTC QLQ C-30**                                                                                                                                                                                                                                                                
   Functioning scales                                                                                                                                                                                                                                                               
    Physical functioning          88.9                           0.4                      87.0                   1.9                     0.752                                                  83.2   1.6   0.003^[\*](#tfn2-crt-2018-053){ref-type="table-fn"}^      86.2   1.8   0.480
    Role functioning              91.2                           0.5                      88.4                   2.1                     0.619                                                  88.0   1.8   0.350                                                     88.9   2.1   0.725
    Emotional functioning         85.5                           0.5                      80.9                   2.2                     0.178                                                  81.0   1.9   0.097                                                     80.2   2.1   0.068
    Cognitive functioning         86.4                           0.5                      83.9                   2.2                     0.683                                                  84.5   1.9   0.747                                                     84.0   2.1   0.673
    Social functioning            93.3                           0.5                      85.7                   2.2                     0.004^[\*](#tfn2-crt-2018-053){ref-type="table-fn"}^   89.2   1.8   0.138                                                     83.3   2.1   \< 0.001^[\*](#tfn2-crt-2018-053){ref-type="table-fn"}^
   Overall quality of life        61.4                           0.5                      62.3                   2.1                     0.980                                                  65.1   1.8   0.204                                                     64.8   2     0.353
   Symptom scales                                                                                                                                                                                                                                                                   
    Fatigue                       20.8                           0.5                      24.2                   2.4                     0.523                                                  25.9   2     0.077                                                     22.9   2.3   0.809
    Nausea and vomiting           5.6                            0.4                      1.7                    1.7                     0.119                                                  4.1    1.5   0.761                                                     3.5    1.6   0.584
    Pain                          8.7                            0.5                      6.7                    2.2                     0.803                                                  15.1   1.9   0.006^[\*](#tfn2-crt-2018-053){ref-type="table-fn"}^      10.8   2.1   0.787
    Dyspnea                       10.4                           0.5                      15.1                   2.5                     0.262                                                  16.7   2.1   0.020^[\*](#tfn2-crt-2018-053){ref-type="table-fn"}^      11.8   2.4   0.941
    Sleep disturbance             14.4                           0.6                      13.0                   2.8                     0.960                                                  17.4   2.3   0.597                                                     18.9   2.6   0.364
    Appetite loss                 11.3                           0.6                      4.0                    2.5                     0.027^[\*](#tfn2-crt-2018-053){ref-type="table-fn"}^   7.7    2.1   0.365                                                     3.6    2.4   0.011^[\*](#tfn2-crt-2018-053){ref-type="table-fn"}^
    Constipation                  12.6                           0.6                      16.3                   2.8                     0.593                                                  17.5   2.4   0.199                                                     14.5   2.7   0.905
    Diarrhea                      9.1                            0.5                      11.1                   2.4                     0.853                                                  11.0   2.1   0.821                                                     13.8   2.3   0.211
    Financial difficulties        6.3                            0.5                      15.8                   2.4                     0.001^[\*](#tfn2-crt-2018-053){ref-type="table-fn"}^   17.4   2.1   \< 0.001^[\*](#tfn2-crt-2018-053){ref-type="table-fn"}^   20.3   2.3   \< 0.001^[\*](#tfn2-crt-2018-053){ref-type="table-fn"}^
  **Functional social support**                                                                                                                                                                                                                                                     
   Affective support              6.3                            0.1                      7.2                    0.3                     0.047^[\*](#tfn2-crt-2018-053){ref-type="table-fn"}^   7.3    0.3   0.005^[\*](#tfn2-crt-2018-053){ref-type="table-fn"}^      7.9    0.3   \< 0.001^[\*](#tfn2-crt-2018-053){ref-type="table-fn"}^
   Confidant support              10.5                           0.1                      11.9                   0.5                     0.047^[\*](#tfn2-crt-2018-053){ref-type="table-fn"}^   11.9   0.4   0.012^[\*](#tfn2-crt-2018-053){ref-type="table-fn"}^      12.4   0.5   0.001^[\*](#tfn2-crt-2018-053){ref-type="table-fn"}^
  **Depression**                  2.9                            0.1                      3.2                    0.5                     0.947                                                  3.2    0.4   0.924                                                     2.8    0.5   0.996

Adj. mean, adjusted mean by analysis of co-variance with age, sex, education, employment status, smoking, alcohol consumption as covariates; SE, standard error; EORTC QLQ C-30, European Organization for Research and Treatment of Cancer.

p \< 0.05.
